Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號 規(guī)格
Recombinant Aspergillus clavatus Protein dml1 (dml1) CSB-YP373728AVC
CSB-EP373728AVC
CSB-BP373728AVC
CSB-MP373728AVC
CSB-EP373728AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus ATP-dependent RNA helicase drs1 (drs1), partial CSB-YP373729AVC
CSB-EP373729AVC
CSB-BP373729AVC
CSB-MP373729AVC
CSB-EP373729AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Protein ssh4 (ssh4), partial CSB-YP373730AVC
CSB-EP373730AVC
CSB-BP373730AVC
CSB-MP373730AVC
CSB-EP373730AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus tRNA-dihydrouridine (47) synthase [NAD (P) (+)], partial CSB-YP373731AVC
CSB-EP373731AVC
CSB-BP373731AVC
CSB-MP373731AVC
CSB-EP373731AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus PAB-dependent poly (A)-specific ribonuclease subunit pan3, partial CSB-YP373732AVC
CSB-EP373732AVC
CSB-BP373732AVC
CSB-MP373732AVC
CSB-EP373732AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Pentafunctional AROM polypeptide (aroM), partial CSB-YP373733AVC
CSB-EP373733AVC
CSB-BP373733AVC
CSB-MP373733AVC
CSB-EP373733AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Mitogen-activated protein kinase hog1 (hog1) CSB-YP373734AVC
CSB-EP373734AVC
CSB-BP373734AVC
CSB-MP373734AVC
CSB-EP373734AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Chitin synthase export chaperone (chs7), partial CSB-YP373735AVC1
CSB-EP373735AVC1
CSB-BP373735AVC1
CSB-MP373735AVC1
CSB-EP373735AVC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Probable quinate permease (qutD), partial CSB-YP373736AVC
CSB-EP373736AVC
CSB-BP373736AVC
CSB-MP373736AVC
CSB-EP373736AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Mitochondrial outer membrane protein iml2 (iml2), partial CSB-YP373737AVC1
CSB-EP373737AVC1
CSB-BP373737AVC1
CSB-MP373737AVC1
CSB-EP373737AVC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Probable alpha-N-arabinofuranosidase C (abfC), partial CSB-YP373738AVC
CSB-EP373738AVC
CSB-BP373738AVC
CSB-MP373738AVC
CSB-EP373738AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Probable E3 ubiquitin-protein ligase hulA (hulA), partial CSB-YP373739AVC
CSB-EP373739AVC
CSB-BP373739AVC
CSB-MP373739AVC
CSB-EP373739AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Ribosome biogenesis protein erb1 (erb1), partial CSB-YP373740AVC
CSB-EP373740AVC
CSB-BP373740AVC
CSB-MP373740AVC
CSB-EP373740AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Pheromone-processing carboxypeptidase kex1 (kex1), partial CSB-YP373741AVC
CSB-EP373741AVC
CSB-BP373741AVC
CSB-MP373741AVC
CSB-EP373741AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Type 1 phosphatases regulator ypi1 (ypi1) CSB-YP373742AVC
CSB-EP373742AVC
CSB-BP373742AVC
CSB-MP373742AVC
CSB-EP373742AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Autophagy-related protein 8 (atg8) CSB-YP373743AVC
CSB-EP373743AVC
CSB-BP373743AVC
CSB-MP373743AVC
CSB-EP373743AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Metacaspase-1A (casA), partial CSB-YP373744AVC
CSB-EP373744AVC
CSB-BP373744AVC
CSB-MP373744AVC
CSB-EP373744AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Protein sds23 (sds23), partial CSB-YP373745AVC
CSB-EP373745AVC
CSB-BP373745AVC
CSB-MP373745AVC
CSB-EP373745AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Probable zinc metalloprotease ACLA_028640 (ACLA_028640), partial CSB-YP373746AVC
CSB-EP373746AVC
CSB-BP373746AVC
CSB-MP373746AVC
CSB-EP373746AVC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Aspergillus clavatus Patatin-like phospholipase domain-containing protein ACLA_029670 (ACLA_029670), partial CSB-YP373747AVC1
CSB-EP373747AVC1
CSB-BP373747AVC1
CSB-MP373747AVC1
CSB-EP373747AVC1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們在線留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>